Flagship startup that aims to treat ‘any disease’ raises $123M

When four-year-old biotech startup Cellarity emerged from stealth in December 2019, it laid out an ambitious vision: to combine cellular biology with machine learning to develop treatments for all diseases. Now, several high-profile investors are joining founding investor Flagship Pioneering in supporting Cellarity’s approach. The startup just closed a $123 million Series B round from…

Read More